Journal of Organic Chemistry p. 10605 - 10616 (2013)
Update date:2022-08-04
Topics:
Davis, Tyler A.
Vilgelm, Anna E.
Richmond, Ann
Johnston, Jeffrey N.
Chiral nonracemic cis-4,5-bis(aryl)imidazolines have emerged as a powerful platform for the development of cancer chemotherapeutics, stimulated by the Hoffmann-La Roche discovery that Nutlin-3 can restore apoptosis in cells with wild-type p53. The lack of efficient methods for the enantioselective synthesis of cis-imidazolines, however, has limited their more general use. Our disclosure of the first enantioselective synthesis of (-)-Nutlin-3 provided a basis to prepare larger amounts of this tool used widely in cancer biology. Key to the decagram-scale synthesis described here was the discovery of a novel bis(amidine) organocatalyst that provides high enantioselectivity at warmer reaction temperature (-20 C) and low catalyst loadings. Further refinements to the procedure led to the synthesis of (-)-Nutlin-3 in a 17 g batch and elimination of all but three chromatographic purifications.
View MoreHUNAN CHEMAPI BIOLOGICAL TECHNOLOGY CO.,LTD.
Contact:+86-186-02659358
Address:1004, building 3, Wanke Jinsemaitianyuan, 498 Guitang Road, Yuhua District, Changsha City, Hunan Province, China
Contact:86-379-63338609
Address:Jiudian Village,Deting Town,Song County,Luoyang
Tianjin SPHINX SCIENTIFIC LAB.
Contact:+86-022-66211289
Address:Tianda high-tech Park. No.80,the 4th Avenue
Contact:86-21-57725962
Address:shanghai
website:http://www.np-chem.com
Contact:0086-25-52346877
Address:199, Jian Ye Road, Nanjing, China
Doi:10.1016/j.jorganchem.2011.11.001
(2012)Doi:10.1016/j.bmcl.2012.10.062
(2012)Doi:10.1039/c1dt11644d
(2012)Doi:10.3184/174751916X14655742365588
(2016)Doi:10.1016/j.bmc.2011.11.010
(2012)Doi:10.1016/j.bmcl.2011.10.119
(2012)